Correlation Analysis of the TP53 Mutation With Clinical Characteristics in the Prognosis of Non-Small Cell Lung Cancer.

Background: Non-small cell lung cancer (NSCLC) with mutations has a worse prognosis. It was generally more resistant to chemotherapy and radiation. Our aim was to investigate the correlation between the co-mutated gene and clinical features, and prognostic value in patients with NSCLC.

Methods: Seventy-three patients with a diagnosis of NSCLC at our hospital were recruited. They were divided into the mutation status (minor) ( MU) and wild-type (major) ( WT) groups according to their clinical characteristics after their mutation data and clinical information were collected. Serum markers were compared between groups using Mann-Whitney test. Other clinical factors were compared between groups using χ2 test and Fisher exact test. The log-rank test was used to compare survival curves.

Results: Of the 73 patients with NSCLC, 37 (50.68%) were found to carry mutation. MU and WT groups (n = 36) showed a significant difference in the number of smokers, incidence of squamous cell carcinoma, mutation, and number of advanced patients (P < .05), while gender, age, lymph node metastasis, and mutation did not differ significantly between the 2 groups. The survival curves in the TP53/KRAS and the co-mutation groups suggest that patients with NSCLC may have a shorter progression-free survival (PFS) if they carry one of the 2 types of co-mutation.

Conclusions: gene mutations are more common in patients with NSCLC and squamous cell carcinoma. New predictive markers for NSCLC prognosis may be and co-mutations.